Tiwary Pooja, Oswal Krishil, Varghese Ryan, Anchan Harsh, Gupta Pardeep
Department of Pharmacy Practice, Poona College of Pharmacy, Bharati Vidyapeeth (Deemed to be) University, Pune 411038, India.
Department of Pharmaceutical Sciences, Philadelphia College of Pharmacy, Saint Joseph's University, Philadelphia, PA 19104, USA.
Chem Phys Lipids. 2025 Aug;270:105510. doi: 10.1016/j.chemphyslip.2025.105510. Epub 2025 Jun 6.
Prostate cancer (PC) is one of the most prevalent malignancies among men, with a staggering 1.5 million new cases and 350,000 deaths reported globally in 2022. Conventional treatment methods, including chemotherapy, radiation therapy, surgery, and hormonal therapy, often encounter significant challenges such as systemic toxicity and diminished efficacy, particularly in the advanced stages of the disease. Treatment of prostate cancer remains a formidable challenge because of the poor water solubility of many chemotherapeutic agents, which severely limits their bioavailability. However, the rise of targeted therapies has catalyzed the development of innovative drug delivery systems designed to enhance the bioavailability and precision of therapeutic agents. Solid lipid nanoparticles (SLNs) are a promising solution that can effectively encapsulate chemotherapeutic agents and genetic materials. Their unique attributes, such as biocompatibility, controlled release profile, and customizable surface properties, make them advantageous alternatives to conventional treatment strategies, effectively addressing the inherent limitations of prostate cancer therapy.
To provide the context, relevant publications were searched on Google Scholar, PubMed, Science Direct, Dimension AI, and EBSCO Host using specific keywords such as controlled drug release, cationic surfactants, drug delivery, drug loading, drug encapsulation lipid, prostate cancer, surface modification, solid lipid nanoparticles (SLNs), tumor microenvironment, to list a few. We did not add any limits to the publication date during the inclusion of papers. However, it is noteworthy that the initial reports including the aforementioned keywords have been published starting from 2010.
SLNs demonstrate substantial potential as effective nanocarriers for precise delivery of chemotherapeutic agents and genetic materials to prostate cancer cells. Their targeted delivery to these cells by surface modification with suitable ligands, antigens, peptides, and other recognition molecules has enhanced therapeutic efficacy. Further research on the interaction of SLN with the tumor environment is imperative to fully comprehend the uptake pathways. Extensive translation and preclinical studies are required to determine the safety and efficacy of SLNs before their use in clinical settings.
前列腺癌（PC）是男性中最常见的恶性肿瘤之一，2022年全球报告了惊人的150万新病例和35万例死亡。传统的治疗方法，包括化疗、放疗、手术和激素治疗，常常面临重大挑战，如全身毒性和疗效降低，尤其是在疾病的晚期阶段。由于许多化疗药物的水溶性差，严重限制了它们的生物利用度，前列腺癌的治疗仍然是一项艰巨的挑战。然而，靶向治疗的兴起催化了旨在提高治疗剂生物利用度和精准度的创新药物递送系统的发展。固体脂质纳米粒（SLNs）是一种有前途的解决方案，能够有效地包裹化疗药物和遗传物质。它们独特的属性，如生物相容性、控释特性和可定制的表面性质，使其成为传统治疗策略的有利替代方案，有效解决了前列腺癌治疗的固有局限性。
为提供背景信息，在谷歌学术、PubMed、科学Direct、Dimension AI和EBSCO Host上使用特定关键词进行了相关文献搜索，如控释药物、阳离子表面活性剂、药物递送、药物负载、药物包封脂质、前列腺癌、表面修饰、固体脂质纳米粒（SLNs）、肿瘤微环境等。在纳入论文时，我们没有对发表日期设置任何限制。然而，值得注意的是，包括上述关键词的初始报告自2010年起已发表。
SLNs作为将化疗药物和遗传物质精确递送至前列腺癌细胞的有效纳米载体显示出巨大潜力。通过用合适的配体、抗原、肽和其他识别分子进行表面修饰，它们对这些细胞的靶向递送提高了治疗效果。对SLN与肿瘤环境相互作用的进一步研究对于全面理解摄取途径至关重要。在将SLNs用于临床之前，需要进行广泛的转化和临床前研究以确定其安全性和有效性。
